MedTrace Logo

Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis

NCT00219908 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2005-12-22

No results posted yet for this study

Summary

The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone and interferon beta1b can delay disease progression of at least one point on EDSS scale in patients with clinically very active relapsing-remitting multiple sclerosis.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

Mitoxantrone

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Farmades, Italy

    collaborator UNKNOWN

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Gilles EDAN, Professor · CHU Rennes

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Completion
2006-06-30

Countries

  • France
  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219908 on ClinicalTrials.gov